Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + verubulin
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of carboplatin and verubulin. Carboplatin is an FDA-approved alkylating agent used primarily for treating advanced ovarian cancer. Verubulin is an investigational antineoplastic agent that functions as a small-molecule inhibitor of microtubule formation and is not a substrate for multidrug resistance pumps. The combination has been studied with findings that verubulin's pharmacokinetic parameters remain similar whether used as monotherapy or in combination with carboplatin.
- Brand names
- Paraplatin
- Other names
- carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on carboplatin + verubulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + verubulin.